CalciMedica, Inc. announced positive results from its Phase 2b CARPO trial of Auxora for treating acute pancreatitis, showing significant improvements in patient outcomes, including a 100% reduction in severe respiratory failure for high-dose patients and a median discharge time of 89 hours compared to placebo.